FP012 / FAPON - LARVOL DELTA

Fapon Biopharma and MOTE Therapeutics to Present Dual-Platform B-Cell Immunotherapy Franchise at BIO 2026 (PRNewswire) - "This franchise features two differentiated programs targeting CD19 and BCMA, designed to deliver potent and sustained B-cell depletion: FPE024, a potential best-in-class CD19×BCMA×CD3 tri-specific T-cell engager for autoimmune indications, with IND filing targeted Q1 2027; and MTX001, a CD19×BCMA in vivo CAR-T program powered by the mobilize tLNP platform, with an investigator-initiated first-in-human study expected in Q4 2026....Leading the clinical-stage pipeline is FP008, a global first-in-class PD1×IL10M fusion protein for immuno-oncology, currently in Phase I development with key readout anticipated in 2026....Both FP012 and FPE021 are entering IND-enabling CMC/GLP toxicology in 2026."

First-in-human • IND • New trial • P1 data • Preclinical • Gastrointestinal Cancer • Immunology • Inflammatory Bowel Disease • Solid Tumor • Systemic Lupus Erythematosus